Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lithium pharmacokinetics in the obese

R A Reiss1, C E Haas, S D Karki

  • 1Center for Clinical Pharmacy Research, School of Pharmacy, University at Buffalo, N.Y.

Clinical Pharmacology and Therapeutics
|April 1, 1994
PubMed
Summary

Obese individuals show different lithium pharmacokinetics, with higher lithium clearance and lower volume of distribution compared to normal weight individuals. This suggests obese patients may need adjusted lithium doses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy.

Clinical and translational science·2016
Same author

Analysis of Health Sector Budget of Nepal.

JNMA; journal of the Nepal Medical Association·2016
Same author

Managing atrial fibrillation in active patients and athletes.

The Physician and sportsmedicine·2010
Same author

Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.

Clinical pharmacology and therapeutics·2009
Same author

A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.

Psychopharmacology bulletin·2002
Same author

Effects of metronidazole on hepatic CYP3A4 activity.

Pharmacotherapy·2001

Area of Science:

  • Pharmacokinetics
  • Obesity Research
  • Clinical Pharmacology

Background:

  • Investigating lithium disposition in obese versus normal weight individuals is crucial for understanding drug efficacy and safety.
  • Obesity significantly alters body composition and fluid volumes, potentially impacting drug pharmacokinetics.

Purpose of the Study:

  • To compare the disposition of lithium in obese subjects versus normal weight volunteers.
  • To determine if obesity affects lithium clearance and volume of distribution.

Main Methods:

  • Oral lithium citrate administration to ten obese and eight normal weight volunteers.
  • Blood sampling over 48 hours, creatinine clearance, and total body water determination.
  • Comparison of pharmacokinetic parameters between the two groups.

Related Experiment Videos

Main Results:

  • Lithium clearance (CLLi) was significantly higher in obese subjects (33.9 ml/min) than controls (23.0 ml/min).
  • Steady-state volume of distribution (VSS) was significantly lower in obese subjects (0.42 L/kg) than controls (0.66 L/kg).
  • VSS correlated with ideal body weight and fat-free mass; CLLi correlated with total body weight.

Conclusions:

  • Lithium pharmacokinetics differ significantly between obese and normal weight individuals.
  • Obese patients may require higher lithium maintenance doses to achieve therapeutic serum concentrations.
  • These findings highlight the importance of considering body weight in lithium dosing strategies.